Uromodulin gene polymorphisms in patients with cast nephropathy in multiple myeloma


Cite item

Full Text

Abstract

Aim. To investigate the nature of mutations in exons 4 and 5 of the uromodulin (UM) gene, including in the area encoding the domain of 8 cysteines (D8C), in patients with multiple myeloma (MM) with the secretion of monoclonal light chains (LC) in cast nephropathy (CN) and without kidney injury. Subjects and methods. The investigation enrolled 24 patients in MM remission, who were observed to have monoclonal LC secretion at onset. Group 1 included 14 patients with CN; Group 2 consisted of 10 patients with normal renal function (a comparison group). The compared groups did not differ in the number of serum and urinary monoclonal LCs. Genomic DNA was extracted from the peripheral blood samples of patients. The nucleotide sequence of exons 4 and 5 of the UM gene was determined by the Sanger method. Results. No differences were found in the frequency of polymorphisms depending on the severity of kidney injury. The missense mutation p.142R>R/Q in the UM gene, which had not been previously described, was discovered. Conclusion. The patients with MM were not found to have statistically significant differences in the frequency and nature of polymorphisms of exons 4 and 5 in the UM gene, including in the area encoding D8C, in CN without kidney injury.

About the authors

I G Rekhtina

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

L P Mendeleeva

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

B V Biderman

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

M V Solovyev

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

A B Sudarikov

ФГБУ «Гематологический научный центр» Минздрава России

Москва, Россия

References

  1. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant. 1998;13(6):1438-1445. https://doi.org/10.1093/ndt/13.6.1438
  2. Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Lacy M, Dispenzieri A, Rajkumar SV, Kyle RA, Leung N C. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012; 59(6):786-794. https://doi.org/10.1053/j.ajkd.2011.12.028
  3. Рехтина И.Г., Менделеева Л.П., Бирюкова Л.С. Диализзависимая почечная недостаточность у больных множественной миеломой: факторы обратимости. Терапевтический архив. 2015; 7:72-76. https://doi.org/10.17116/terarkh201587772-76
  4. Huang ZQ, Sanders PW. Localization of a Single Binding Site for Immunoglobulin Light Chains on Human Tamm-Horsfall Glycoprotein. J Clin Invest. 1997;99:732-736. https://doi.org/10.1172/jci119218
  5. Ying W-Z, Sanders PW. Mapping the Binding Domain of Immunoglobulin Light Chains for Tamm-Horsfall Protein. American Journal of Pathology. 2001;158:1859-1866. https://doi.org/10.1172/jci119218
  6. Ying W-Z, Allen CE., Curtis LM, Aaron KJ, Sanders PW. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest. 2012;122(5):1777-1785. https://doi.org/10.1172/JCI46490
  7. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV M., Kumar S., Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson S, Caers J, Usmani S, Lahuerta J, Johnsen H, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle R, Anderson K, Durie B, Miguel J. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;15(12):538-548. https://doi.org/10.1016/S1470-2045(14)70442-5
  8. Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, Child AJ. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108(6):2013-2019. https://doi.org/10.1182/blood-2006-03-008953
  9. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845-1851. https://doi.org/10.1056/nejm199106273242603
  10. Herrera GA. Renal manifestations of plasma cell dyscrasias. An appraisal from the patients’ bedside to the research laboratory. Ann Diagn Pathol. 2000;4:174-200. https://doi.org/10.1016/s1092-9134(00)90042-x
  11. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17(9):2533-2545. https://doi.org/10.1681/asn.2006020139
  12. Sikkink LA, Ramirez-Alvarado M. Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases. Amyloid. 2008;15(1):29-39. https://doi.org/10.1080/13506120701815324
  13. Wall JS, Gupta V, Wilkerson M, Schell M, Loris R, Adams P, Solomon A, Stevens F, Dealwis C. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins. J Mol Recognit. 2004;17(4):323-331. https://doi.org/10.1002/jmr.681
  14. Dealwis C, Wall J. Towards understanding the structure-function relationship of human amyloid disease. Curr Drug Targets. 2004; 5:159-171. https://doi.org/10.2174/1389450043490550
  15. Kaplan B, Ramirez-Alvarado M, Sikkink L, Golderman S, Dispenzieri A, Livneh A, Gallo G. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol. 2009;144:705-715. https://doi.org/10.1111/j.1365-2141.2008.07522.x
  16. Denoroy L, Deret S, Aucouturier P. Overpresentation of V kappa IV subgroup in light chain deposition disease. Immunol Lett. 1994;42:63-66. https://doi.org/10.1016/0165-2478(94)90036-1
  17. Khamlichi AA, Aucouturier P, Silvain C, Bauwens M, Touchard G, Preud’homme J.-L, Nau F, Cogne M. Primary structure of a monoclonal κ chain in myeloma with light chain deposition disease. Clinical & Experimental Immunology. 2008; 87(1):122-126. https://doi.org/10.1111/j.1365-2249.1992.tb06424.x
  18. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101:3801-3808. https://doi.org/10.1182/blood-2002-09-2707
  19. Gu M, Wilton R, Stevens FJ. Diversity and diversification of light chains in myeloma: the specter of amyloidogenesis by proxy. Contrib Nephrol. 2007;153:156-181. https://doi.org/10.1159/000096766
  20. Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with Al amyloidosis. PLoS ONE. 2009;4(4):e5169. https://doi.org/10.1371/journal.pone.0005169
  21. Горчакова С.В., Рехтина И.Г., Никитин Е.А., Каменский П.А., Судариков А.Б., Бирюкова Л.С. Первичная структура вариабельного региона легких цепей в патогенезе миеломной нефропатии. Гематология и трансфузиология. 2009;6:28-33.
  22. Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: Biology and clinical relevance. Am J Kidney Dis. 2003;42:658-676. https://doi.org/10.1016/s0272-6386(03)00829-1
  23. Hart TC, Gorry MC, Hart PS, Woodard AS, Shihabi Z, Sandhu J, Shirts B, Xu L, Zhu H, Barmada MM, Bleyer AJ. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet. 2002;39:882-892. https://doi.org/10.1136/jmg.39.12.882
  24. Rampoldi L, Caridi G, Santon D, Boaretto F, Bernascone I, Lamorte G, Tardanico R, Dagnino M, Colussi G, Scolari F, Ghiggeri GM, Amoroso A, Casari G. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet. 2003;12:3369-3384. https://doi.org/10.1093/hmg/ddg353
  25. Dahan K, Devuyst O, Smaers M, Vertommen D, Loute G, Poux JM, Viron B, Jacquot C, Gagnadoux MF, Chauveau D, Büchler M, Cochat P, Cosyns JP, Mougenot B, Rider MH, Antignac C, Verellen-Dumoulin C, Pirson Y. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol. 2003;14:2883-2893. https://doi.org/10.1097/01.asn.0000092147.83480.b5
  26. Olden M, Corre T, Hayward C, Toniolo D, Ulivi S, Gasparini P, Pistis G, Hwang SJ, Bergmann S, Campbell H, Cocca M, Gandin I, Girotto G, Glaudemans B, Hastie ND, Loffing J, Polasek O, Rampoldi L, Rudan I, Sala C, Traglia M, Vollenweider P, Vuckovic D, Youhanna S, Weber J, Wright AF, Kutalik Z, Bochud M, Fox CS, Devuyst O. Common variants in UMOD associate with urinary uromodulin levels: a meta-analysis. J Am Soc Nephrol. 2014;25(8):1869-1882. https://doi.org/10.1681/ASN.2013070781
  27. Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O. The rediscovery of uromodulin (Tamm—Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int. 2011;80:338-347. https://doi.org/10.1038/ki.2011
  28. Moskowitz JL, Piret SE, Lhotta K, Kitzler TM, Tashman AP, Velez E, Thakker RV, Kotanko P. Association between genotype and phenotype in uromodulin-associated kidney disease. Clin J Am Soc Nephrol. 2013;8(8):1349-1357. https://doi.org/10.2215/CJN.11151012
  29. Scolari F, Izzi C, Ghiggeri . Uromodulin: from monogenic to multifactorial diseases. Nephrol Dial Transplant. 2015;30(8):1250-1256. https://doi.org/10.1093/ndt/gfu300
  30. Bollée G, Dahan K, Flamant M, Morinière V, Pawtowski A, Heidet L, Lacombe D, Devuyst O, Pirson Y, Antignac C, Knebelmann B. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clin J Am Soc Nephrol. 2011;6:2429-2438. https://doi.org/10.2215/CJN.01220211
  31. Köttgen A, Yang Q, Shimmin LC, Tin A, Schaeffer C, Coresh J, Liu X, Rampoldi L, Hwang SJ, Boerwinkle E, Hixson JE, Kao WH, Fox CS. Association of estimated glomerular filtration rate and urinary uromodulin concentrations with rare variants identified by UMOD gene region sequencing. PLoS One. 2012; 7(5):e38311. https://doi.org/10.1371/journal.pone.0038311

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies